According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.
The American Urological Association (AUA) recently published a white paper supporting the use of Advanced Practice Providers (APPs) in caring for patients with genitourinary disease to improve access to care. There is a workforce shortage of 65,000 physicians projected for primary care and specialty medicine by 2025, and APPs could meet up to 70% of patient needs in clinical practice. Additionally, the supply of physician assistants (PAs) and advanced practice registered nurses (APRNs) are expected to continue increasing.
According to the AUA Census, 72.5% of urologists used an APP in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows that patients have demonstrated a growing acceptance of APPs in urology practice settings.
The white paper discusses that most APPs usually work in general urology, and APRNs are more likely than PAs to practice in urology specialty areas such as oncology. Collaborative models involve an APP working with one or more physicians to deliver healthcare services that are supported by jointly developed protocols and practice guidelines. This partnership can also aid in improving workflow and enhancing patient care. The AUA Education Council identified urologic oncology as one of the 6 topic areas to develop training modules for APPs.
APP compensation is also discussed in the white paper through the following 4 payment methods to consider:
APPs can also play an important role in patient care through telehealth through virtual visits after an initial consultation with the urologist. Additionally, telesurgical streaming can enable APPs to virtually scrub in for surgeries for patients they will be providing postoperative care. This also provides valuable training experience for APPs and critical information for the patient’s recovery process.
Meet the Board: Otis Brawley Talks Health, Racial Disparities, Cancer Screenings and More
September 30th 2020This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Listen
3 Upcoming Urothelial Cancer Conferences
August 12th 2021At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Read More
Updated SITC Immunotherapy Guidelines for Urothelial Cancer
August 3rd 2021The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).
Read More